Profile data is unavailable for this security.
About the company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
- Revenue in USD (TTM)0.00
- Net income in USD-359.64m
- Incorporated2012
- Employees53.00
- LocationViking Therapeutics Inc9920 Pacific Heights Blvd, Suite 350SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 704-4660
- Fax+1 (302) 636-5454
- Websitehttps://vikingtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 70.85m | -342.60m | 3.00bn | 252.00 | -- | 5.06 | -- | 42.30 | -4.00 | -4.00 | 0.8355 | 7.09 | 0.0863 | -- | -- | 281,146.80 | -41.73 | -44.39 | -44.98 | -47.63 | -- | -- | -483.57 | -1,390.51 | -- | -- | 0.1044 | -- | 23,359.93 | 132.18 | -26.91 | -- | 63.78 | -- |
| Ideaya Biosciences Inc | 218.71m | -113.70m | 3.01bn | 145.00 | -- | 2.94 | -- | 13.78 | -1.30 | -1.30 | 2.46 | 11.65 | 0.1959 | -- | 73.20 | 1,508,345.00 | -10.18 | -18.78 | -10.68 | -20.00 | -- | -- | -51.99 | -185.86 | -- | -- | 0.00 | -- | 3,024.43 | 62.11 | 58.58 | -- | 36.87 | -- |
| Edgewise Therapeutics Inc | 0.00 | -167.80m | 3.09bn | 146.00 | -- | 5.86 | -- | -- | -1.63 | -1.63 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -32.29 | -28.13 | -33.96 | -29.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.40 | -- | 4.75 | -- |
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.15bn | 102.00 | -- | 5.60 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.18bn | 503.00 | -- | 3.08 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.30bn | 2.90k | -- | 3.26 | -- | 3.63 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.51bn | 233.00 | -- | 7.63 | -- | 158.63 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -345.91m | 3.64bn | 358.00 | -- | 6.02 | -- | 485.72 | -4.36 | -4.36 | 0.0946 | 7.27 | 0.0105 | -- | 5.28 | 20,949.72 | -48.34 | -27.62 | -51.10 | -28.67 | -- | -- | -4,612.13 | -2,733.56 | -- | -- | 0.00 | -- | -- | -25.26 | -47.62 | -- | -21.24 | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.69bn | 53.00 | -- | 5.74 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 3.81bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.84bn | 796.00 | 9.87 | 3.12 | 9.52 | 3.58 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 3.93bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.20bn | 594.00 | -- | 3.87 | -- | 545.84 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.37bn | 103.00 | -- | 11.50 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
Data as of Mar 04 2026. Currency figures normalised to Viking Therapeutics Inc's reporting currency: US Dollar USD
31.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.13m | 8.08% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 5.52m | 4.88% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.48m | 3.97% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.45m | 3.93% |
| Two Sigma Investments LPas of 31 Dec 2025 | 2.44m | 2.16% |
| Two Sigma Advisers LPas of 31 Dec 2025 | 2.13m | 1.88% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.99m | 1.76% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 1.90m | 1.68% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.72m | 1.52% |
| Jane Street Capital LLCas of 31 Dec 2025 | 1.50m | 1.33% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
